Merck's CEO Belén Garijo Champions Resilience and Growth Amidst 2023's Market Challenges, Sets Strategic Path for Sustainable Success

Financial results of fiscal 2023 Net sales decrease organically by 1.6% to € 21.0 billion EBITDA pre down organically by 9.0% to € ...

March 07, 2024 | Thursday | News
ICON CEO, Dr. Steve Cutler, Highlights Strong Performance and Affirms 2024 Financial Guidance

ICON plc (NASDAQ:ICLR), a global leader in healthcare intelligence and clinical research,  announced its financial results for the fourth quarter and ...

February 22, 2024 | Thursday | Company results
Bio-Rad's CEO, Norman Schwartz, Anticipates Sector Rebound in 2024 Amid Fourth Quarter Challenges

Bio-Rad Laboratories Inc. reports a 6.7% decrease in fourth-quarter net sales compared to 2022, largely attributed to ongoing weakness in biopharma markets...

February 16, 2024 | Friday | Company results
CEO Ari Bousbib Commends IQVIA's Resilience Amidst Challenging 2023 Landscape

  -IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a global leader in advanced analytics, technology solutions, and clinical research services ...

February 15, 2024 | Thursday | Company results
Catalent CEO Alessandro Maselli Celebrates Q2 Triumphs, Forges Transformative Alliance with Novo Holdings to Supercharge Growth

Q2'24 net revenue of $1.03 billion decreased 10% as reported, or 11% in constant currency(1), compared to Q2'23. Q2'24 net revenue, excluding COVID...

February 12, 2024 | Monday | Company results
Illumina Surpasses Expectations in Q4, Driven by NovaSeq X Sales, CEO Jacob Thaysen Reports

Illumina, Inc. (Nasdaq: ILMN) ("Illumina" or the "company")  disclosed its financial performance for the fourth quarter and fiscal year 2023, includin...

February 09, 2024 | Friday | Company results
CEO Pascal Soriot Highlights AstraZeneca's Strong Financial Performance and Scientific Progress in 25th Anniversary Year

Key Points: AstraZeneca announces robust financial performance for the full year and fourth quarter of 2023, marked by strong revenue growth and s...

February 08, 2024 | Thursday | Company results
Bristol Myers Squibb CEO Christopher Boerner Highlights Strong Q4 Performance and Strategic Actions for Sustainable Growth in 2024

Bristol Myers Squibb (NYSE: BMY) announced its financial results for the fourth quarter and full year of 2023, demonstrating robust performance, pipeline a...

February 05, 2024 | Monday | Company results
Chairman Marc N. Casper Commends Team Effort as Thermo Fisher Scientific Thrives in 2023

“Thanks to the strong contributions from our team, we delivered differentiated performance in 2023 and enabled our customers’ success,” s...

January 31, 2024 | Wednesday | Company results
Novartis CEO Vas Narasimhan Affirms Company's Transformation and Growth Targets: Strong Operational Performance and Ten Positive Phase 3 Readouts Highlight Strategic Success

Novartis, under the leadership of CEO Vas Narasimhan, has announced robust financial results for the full year of 2023. The company reported a 10% growth i...

January 31, 2024 | Wednesday | Company results
Lonza's CEO Albert M. Baehny Steers Company to Stellar Success in 2023, Defying Economic Headwinds with Robust Financial Performance and Ambitious Growth Initiatives

Robust sales of CHF 6.7 billion, delivering 10.9%1 CER sales growth CORE EBITDA of CHF 2 billion, resulting in a margin of 29.8% Continued growth inves...

January 26, 2024 | Friday | Company results
Robert B. Ford, CEO of Abbott, Highlights Portfolio Strength and Diversity as Key to 2023 Success and Foresees Continued Growth in 2024 and Beyond.

Fourth-quarter reported sales increased 1.5 percent; organic sales growth for the underlying base business increased 11.0 percent Full-year 2023 reporte...

January 24, 2024 | Wednesday | Company results
Citius Pharmaceuticals, Guided by CEO Leonard Mazur, Charts a Promising Course for 2024 with Pipeline Success and Strategic Moves

Citius Pharmaceuticals, Inc. ("Citius" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercial...

January 03, 2024 | Wednesday | News
Geoff Martha, CEO of Medtronic, Declares a Surge in Durable Mid-Single Digit Revenue Growth, Backed by Strong Fundamentals and Game-Changing Innovations

Medtronic plc announced financial results for its second quarter of fiscal year 2024 (FY24), which ended October 27, 2023. Key Highlights Revenue of $8...

November 22, 2023 | Wednesday | Company results

Survey Box

Poll of the Week

Which area of biopharmaceutical research excites you the most?

× Please select an option to participate in the poll.
× You have successfully cast your vote.
 {{ optionDetail.option }}  {{ optionDetail.percentage }}%
 {{ optionDetail.percentage }}% Complete
More polls
Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

© 2024 Biopharma Boardroom. All Rights Reserved.


Forgot your password?



Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in